Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.
Purity:
95.00%
CAS Number:
[2428381-55-7]
Target:
Interleukin|||Others
* VAT and and shipping costs not included. Errors and price changes excepted